Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Deffered Revenue (2022 - 2024)

Century Therapeutics (IPSC) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $109.8 million as the latest value for Q3 2024.

  • Quarterly Non-Current Deffered Revenue fell 2.12% to $109.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $109.8 million through Sep 2024, down 2.12% year-over-year, with the annual reading at $111.4 million for FY2023, 0.49% changed from the prior year.
  • Non-Current Deffered Revenue for Q3 2024 was $109.8 million at Century Therapeutics, roughly flat from $109.8 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $115.8 million in Q1 2022, with the low at $109.2 million in Q2 2023.
  • Average Non-Current Deffered Revenue over 3 years is $111.2 million, with a median of $110.8 million recorded in 2022.
  • Peak annual rise in Non-Current Deffered Revenue hit 1.09% in 2023, while the deepest fall reached 5.17% in 2023.
  • Over 3 years, Non-Current Deffered Revenue stood at $110.8 million in 2022, then grew by 0.49% to $111.4 million in 2023, then decreased by 1.45% to $109.8 million in 2024.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $109.8 million, $109.8 million, and $110.3 million for Q3 2024, Q2 2024, and Q1 2024 respectively.